Plasma prolactin levels are associated with the severity of illness in drug-naive first-episode psychosis female patients
Patients with schizophrenia frequently present hyperprolactinemia as a consequence of antipsychotic treatment. However, an increase in circulating prolactin levels has also been shown in patients without previous treatment. Our objective was to compare prolactin levels between antipsychotic-naive first-episode psychosis (AN-FEP) patients and healthy controls (HC). As part of an FEP program (Programa Asistencial Fases Iniciales de Psicosis [PAFIP]), 270 AN-FEP patients and 153 HC were eligible for this study. Serum prolactin levels were measured by an automated immunochemiluminescent assay. Subjects’ sex and having an AN-FEP diagnosis both had an effect on prolactin levels, with higher levels in women than in men, and in AN-FEP patients than in HC. Moreover, plasma prolactin levels showed a negative correlation with the SAPS scores in AN-FEP female patients. AN-FEP patients have increased levels of prolactin, which might be stress-induced. This, together with the association of higher prolactin with a lower severity of the disease, suggests that prolactin might play a neuroprotective role, especially in women.
KeywordsFirst-episode psychosis Prolactin Schizophrenia Women
The authors wish to thank all PAFIP research team and all patients and family members who participated in the study.
This work was supported by Fundación Instituto de Investigación Marqués de Valdecilla (NCT0235832 and NCT02534363).
Compliance with ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Conflict of interest
M.D-A. held a Rio Hortega Research Grant from Instituto de Salud Carlos III. J.L. has received honoraria for lectures or advisory boards from Janssen, Otsuka, and Lundbeck. B. C.-F. received in the last 3 years research funding from Lundbeck that was deposited into research accounts at the CIBERSAM. B. C.-F. has received in the last 3 years honoraria for his participation as a speaker at educational events from Otsuka, Lundbeck, and Johnson & Johnson and has been a consultant and/or advisor to or has received honoraria from Alkermes, Lundbeck, Otsuka, Casen Recordati, and Teva. D. T.-G. declares that she has no conflict of interest. R. A.-A. declares that she has no conflict of interest. V. O.-G. declares that he has no conflict of interest.
- Addington D, Addington J, Maticka-Tyndale E (1993) Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl (22):39–44Google Scholar
- Andreasen N (1984) The Scale for the Assessment of Positive Symptoms (SAPS). The University of Iowa, Iowa City, pp 1–2Google Scholar
- Andreasen NC (1989) Scale for the Assessment of Negative Symptoms (SANS). Br J Psychiatry 155(Suppl 7):53–58Google Scholar
- Crespo-Facorro B, Pelayo-Teran JM, Perez-Iglesias R, Ramirez-Bonilla M, Martinez-Garcia O, Pardo-Garcia G, Vazquez-Barquero JL (2007) Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. J Psychiatr Res 41(8):659–666CrossRefPubMedGoogle Scholar
- Labad J, Stojanovic-Perez A, Montalvo I, Sole M, Cabezas A, Ortega L, Moreno I, Vilella E, Martorell L, Reynolds RM, Gutierrez-Zotes A (2015) Stress biomarkers as predictors of transition to psychosis in at-risk mental states: roles for cortisol, prolactin and albumin. J Psychiatr Res 60:163–169CrossRefPubMedGoogle Scholar
- Lally J, Ajnakina O, Stubbs B, Williams HR, Colizzi M, Carra E, Fraietta S, Gardner-Sood P, Greenwood KE, Atakan Z, Mondelli V, Ismail K, Howes O, Taylor DM, Smith S, Hopkins D, Murray RM, Gaughran F (2017) Hyperprolactinaemia in first episode psychosis - a longitudinal assessment. Schizophr Res 189:117–125CrossRefPubMedGoogle Scholar
- Torner L (2016) Actions of prolactin in the brain: from physiological adaptations to stress and neurogenesis to psychopathology. Front Endocrinol (Lausanne) 7:25Google Scholar